Identification of therapeutic phytochemicals targeting B-cell lymphoma 2 (BCL2) as anti-acute myeloid leukemia agents: An in-silico approach
Abstract
ackground: Acute myeloid leukemia (AML) is a deadly cancer. B cell lymphoma 2 (BCL2) is frequently upregulated in AML and plays a vital role in the viability of both AML and AML stem cells. This study aimed to identify novel phytochemicals against BCL2 and evaluate their pharmacokinetics and toxicity prediction using in-silico tools.
Methods: In-silico screening of phytochemicals against BCL2 active site using the PyRx0.8 AutoDock tool, followed by in silico pharmacokinetic and toxicity predictions was performed. Protein-protein interaction analysis was performed using the STRING database for assessing the interactions between BCL2 and neighboring interacting proteins.
Results: In total, 1106 terpenoid compounds were screened to evaluate their binding affinity toward BCL2. Five natural compounds demonstrated strong binding to the BCL2 protein after extensive screening, detailed interaction analysis, and visual inspections. Notably, these compounds had higher binding energies than the positive control (venetoclax). In addition, these compounds were found to bind to key BCL2 residues and possess good drug-like properties.
Conclusions: The identified phytochemicals represent an important initial step in drug discovery for AML management. Experimental validation is required to optimize the identified phytochemicals as potential BCL2 inhibitors.
Full Text:
PDFReferences
Mortality GBD, Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, (2016); 388(10053): 1459-1544.
Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, (2016); 388(10053): 1545-1602.
Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, (2017); 129(4): 424-447.
Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, (2010); 115(3): 453-474.
Rowe JM. Perspectives on current survival and new developments in AML. Best Practice & Research Clinical Haematology, (2021); 34(1): 101248.
Belka C, Budach W. Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology. International Journal of Radiation Biology, (2002); 78(8): 643-658.
Alam M, Ali S, Mohammad T, Hasan GM, Yadav DK, et al. B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy. International Journal of Molecular Sciences, (2021); 22(19): 10442.
Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi PL, et al. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica, (2022); 107(1): 58-76.
Young AI, Timpson P, Gallego-Ortega D, Ormandy CJ, Oakes SR. Myeloid cell leukemia 1 (MCL-1), an unexpected modulator of protein kinase signaling during invasion. Cell Adhesion & Migration, (2018); 12(6): 513-523.
Kapoor I, Bodo J, Hill BT, Hsi ED, Almasan A. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death & Disease, (2020); 11(11): 941.
Scheffold A, Jebaraj BMC, Stilgenbauer S. Venetoclax: Targeting BCL2 in Hematological Cancers. Recent Results in Cancer Research, (2018); 212: 215-242.
Bohl SR, Bullinger L, Rucker FG. New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise. International Journal of Molecular Sciences, (2019); 20(8): 1983.
Del Prado-Audelo ML, Cortes H, Caballero-Floran IH, Gonzalez-Torres M, Escutia-Guadarrama L, et al. Therapeutic applications of terpenes on inflammatory diseases. Frontiers in Pharmacology, (2021); 12: 704197.
Fan M, Yuan S, Li L, Zheng J, Zhao D, et al. Application of terpenoid compounds in food and pharmaceutical products. Fermentation, (2023); 9(2): 119.
Sabe VT, Ntombela T, Jhamba LA, Maguire GEM, Govender T, et al. Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. European Journal of Medicinal Chemistry, (2021); 224: 113705.
Usha T, Shanmugarajan D, Goyal AK, Kumar CS, Middha SK. Recent Updates on Computer-aided Drug Discovery: Time for a Paradigm Shift. Current Topics in Medicinal Chemistry, (2017); 17(30): 3296-3307.
Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. Journal of Natural Products, (2020); 83(3): 770-803.
Wali AF, Majid S, Rasool S, Shehada SB, Abdulkareem SK, et al. Natural products against cancer: Review on phytochemicals from marine sources in preventing cancer. Saudi Pharmaceutical Journal, (2019); 27(6): 767-777.
Birkinshaw RW, Gong JN, Luo CS, Lio D, White CA, et al. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nature Communications, (2019); 10(1): 2385.
von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Research, (2003); 31(1): 258-261.
Valdes-Jimenez A, Pena-Varas C, Borrego-Munoz P, Arrue L, Alegria-Arcos M, et al. PSC-db: A Structured and Searchable 3D-Database for Plant Secondary Compounds. Molecules, (2021); 26(4): 1124.
Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods in Molecular Biology, (2015); 1263: 243-250.
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, (2017); 7: 42717.
Wei Y, Cao Y, Sun R, Cheng L, Xiong X, et al. Targeting Bcl-2 Proteins in Acute Myeloid Leukemia. Frontiers in Oncology, (2020); 10: 584974.
Bultum LE, Tolossa GB, Lee D. Combining empirical knowledge, in silico molecular docking and ADMET profiling to identify therapeutic phytochemicals from Brucea antidysentrica for acute myeloid leukemia. PLoS One, (2022); 17(7): e0270050.
Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design, (2011); 7(2): 146-157.
Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice. Frontiers in Pharmacology, (2019); 10: 1614.
Newman DJ, Cragg GM. Natural Products as Sources of New Drugs from 1981 to 2014. Journal of Natural Products, (2016); 79(3): 629-661.
Refbacks
- There are currently no refbacks.